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journal homepage: www.elsevier .com/locate/ IPEJAsymptomatic recurrence after AF ablation: Is all lost?As the functionality and usage of permanent pacemakers and
cardiac deﬁbrillators continues to grow, these devices also provide
an opportunistic means of cardiac arrhythmia detection. Ongoing
reﬁnements in device detection algorithms have facilitated the
diagnosis of atrial ﬁbrillation (AF) with a high degree of accuracy
[1]. Not only is this beneﬁcial in corroborating symptomatic events,
but there is a potential for an evolving role in guiding anticoagula-
tion in these patients. Subclinical AF is common in patients with
pacemakers and is associated with increased stroke risk [2,3]. How-
ever, the duration of subclinical AF at which patients may beneﬁt
from anticoagulation is still a matter of debate [4].
In this issue of the Indian Pacing and Electrophysiology Journal,
Osaka Y et al. report on the prevalence of asymptomatic AF recur-
rence after catheter ablation, in 51 patients who had previously un-
dergone pacemaker implantation for sick sinus syndrome [5]. They
measured the AF recurrence rate using a ‘conventional’ follow-up in
the form of 12 lead ECG, Holter monitor and event recorder and
compared this to the recurrence rate observed when conventional
follow-up was complemented by annual pacemaker interrogation.
All participants in this study underwent a comprehensive ablation
protocol that allowed antiarrhythmic drugs to be systematically
discontinued after the procedure. Following wide encircling pul-
monary vein isolation, adenosine was used to unmask dormant
connection and isoproterenol and burst pacing were used to iden-
tify inducible AF. Positive outcomes in these tests served as a basis
for further ablation. During follow-up, pacemaker detected AF was
deﬁned as a sudden increase in heart rate above the programmed
mode switch rate of 170bpm, that lasted more than 30 seconds,
and that was conﬁrmed by a manual review of the electrogram. Ul-
timately, device interrogation demonstrated an incremental detec-
tion of asymptomatic AF. The authors reported that the 5-year AF
free survival rate after a single procedure was 86% using conven-
tional follow-up compared to 58.6% when pacemaker interrogation
was also used, although this did not reach statistical signiﬁcance.
However, this differencewas highly signiﬁcant in patients undergo-
ing multiple procedures, with AF free survival rates of 60.9% and
40.6% respectively.
The topic of subclinical AF is particularly relevant to individuals
undergoing curative catheter ablation. Since the procedure is
generally reserved for highly symptomatic patients, procedural
success is often deﬁned by an absence of symptomatic recurrence.
In this sense, there may be a tendency in patients to assume that a
lack of AF-related symptoms translates into a diminished thrombo-
embolic risk. On the contrary, the ﬁndings in this study reinforces
earlier research demonstrating that a substantial proportion of pa-
tients undergoing ablation have exclusively asymptomatic recur-
rences [6]. Moreover, the failure to identify an independentPeer review under responsibility of Indian Heart Rhythm Society.
http://dx.doi.org/10.1016/j.ipej.2017.08.001
0972-6292/Copyright © 2017, Indian Heart Rhythm Society. Production and hosting by
creativecommons.org/licenses/by-nc-nd/4.0/).clinical predictor of these asymptomatic episodes suggests that
risk stratifying patients to determine who should receive more
rigorous monitoring may not be a feasible option. This result is
consistent with other studies that have failed to reproducibly
isolate any patient characteristic that holds a signiﬁcant predictive
value [6,7]. This shortcoming leads to another important point that
is evident from the results of this study, but perhaps underempha-
sized by the authors. Utilisation of implantable cardiac devices may
represent the only method of arrhythmia monitoring that yields an
adequate detection rate for asymptomatic recurrence. For example,
two-third of patients with AF recurrences were asymptomatic and
in patients undergoing multiple catheter ablations, 10 of the 11
asymptomatic AF recurrences were only detected by pacemaker
interrogation. Of course, some perspective is required here, since
the minimum duration of AF that constitutes a signiﬁcant stroke
risk remains unclear. In this study, the median maximum AF dura-
tion during asymptomatic episodes was only 1 hour as opposed to
15 hours for symptomatic episodes. The current guidelines recom-
mend centring anticoagulation decisions around the patient's
thromboembolic risk proﬁle rather than procedural success [8]. In
this regard, identifying all asymptomatic episodes may not be
important. Nevertheless, there are several retrospective and pro-
spective studies showing that cessation of anticoagulation in
selected patients after successful catheter ablation for AF may not
be associated with increase in stroke risk [9]. The use of continuous
monitoring may provide useful clinical information in such cases.
Furthermore, as catheter ablation techniques for AF are becoming
more reﬁned, studies are being performed to assess changes in
hard end points such as stroke and death. The current AF recur-
rence deﬁnition lacks a physiological basis and AF ablation studies
with continuous rhythm monitoring may provide invaluable infor-
mation to redeﬁne AF recurrence in the future.
In terms of procedural success, the authorsmust be commended
on the 5-year, single-procedure arrhythmia free survival rate of 86%
using conventional monitoring. This compares extremely favour-
ably to the results of a recent meta-analysis, which yielded a pooled
estimate of 66.6% for single procedure freedom fromparoxysmal AF
at 1 year [10]. Nevertheless, when pacemaker detected episodes are
also considered, the 39.1% ﬁve-year recurrence rate serves as a
poignant reminder that even themost comprehensive ablation pro-
cedures have limited long-term success, and reinforces the recent
recommendation for risk factor management in patients undergo-
ing AF ablation [11e13].
In conclusion, the study by Osaka Y et al. progresses an evolving
ﬁeld of continuous cardiac monitoring and subclinical arrhythmia
detection. It reminds us that asymptomatic AF recurrence after
catheter ablation is common and that clinicians need to remain
vigilant, particularly if they are considering discontinuing anticoa-
gulation. Still, questions remain as to which patients shouldElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
A. Thiyagarajah et al. / Indian Pacing and Electrophysiology Journal 17 (2017) 123e124124undergo an intensive rhythm monitoring strategy as well as to the
duration of AF that is clinically signiﬁcant. The recent surge in
studies incorporating implantable cardiac devices will hopefully
bring some clarity to this issue.
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